- Analysis of minimal residual disease (MRD) of protocol ALL IC - BFM 2002: Might the patients be stratified without MRD? +1Publication without faculty affiliation
- Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?2008 | Second Faculty of Medicine
- Assessment of extramedullary leukemic infiltration in childhood acute lymphoblastic leukemia and its clinical use. Review and original data2012 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Medicine in Pilsen, Second Faculty of Medicine
- Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 20082010 | Second Faculty of Medicine
- Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia2013 | Second Faculty of Medicine
- Monitoring of Minimal Residual Disease (MRD) by Polymerase Chain Reaction in Patients Treated for B-Cell Nonhodgkin´s lymphomas (NHL) at the 1st Department of Internal Medicine General Faculty Hospital in PraguePublication without faculty affiliation
- Development of molecular biology methods and their applications in haemato(onco)logy in the last 25 years2019 | Second Faculty of Medicine
- Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma - Residual disease monitoring and a correlation with the disease status2008 | Second Faculty of Medicine
- Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring2006 | Second Faculty of Medicine
- Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?2023 | Second Faculty of Medicine
- Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data2012 | Second Faculty of Medicine
- Quality Control for IG /TR Marker Identification and MRD Analysis2022 | Second Faculty of Medicine
- Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia2013 | Second Faculty of Medicine
- Real-world evidence on prognostic value of minimal residual disease in multiple myeloma: Czech experiencePublication without faculty affiliation
- Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia2003 | Second Faculty of Medicine
- The use of formalin-fixed, paraffin-embedded lymph node samples for the detection of minimal residual disease in mantle cell lymphoma2015 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine
- The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL2015 | Second Faculty of Medicine
- A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients2013 | First Faculty of Medicine, Third Faculty of Medicine
- Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data2007 | Second Faculty of Medicine
- Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study2021 | Second Faculty of Medicine
- Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study2022 | Second Faculty of Medicine
- Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Aetiology of childhood ALL and AML, molecular genetics and minimal residual disease2015 | Second Faculty of Medicine
- CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment2017 | Second Faculty of Medicine
- Minimal residual disease – detection possibilities in haematological and non-haematological malignancies2013 | Second Faculty of Medicine
- Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: Quality assurance on behalf of SIOPEN-R-NET2007 | Second Faculty of Medicine
- WT1 protein expression in childhood acute leukemia2008 | Second Faculty of Medicine
- Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.2010 | First Faculty of Medicine
- Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS2019 | Second Faculty of Medicine